Qiagen NV

Research Qiagen NV (QGEN) on Bullrun: valuation model: 9.0% undervalued, market cap USD 8.21B, P/E 20.6, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerQGEN
• ExchangeNYSE
• CountryNetherlands
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyUSD
• Valuation signal9.0% undervalued
• Market capUSD 8.21B
• P/E20.6
• Dividend yield0.6%
• Financial periodFY2025
• RevenueUSD 2.09B
• Revenue growth5.7%
• Net incomeUSD 436.97M
• Free cash flowUSD 615.21M
• Gross margin61.9%

Valuation Snapshot

Bullrun's latest valuation model marks Qiagen NV as 9.0% undervalued; latest market cap is USD 8.21B; P/E is 20.6; dividend yield is 0.6%.

About Qiagen NV

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids;

Frequently asked questions

Is Qiagen NV overvalued or undervalued?

Bullrun's valuation model currently marks Qiagen NV as 9.0% undervalued.

What is Qiagen NV's market cap?

Qiagen NV's market capitalization is USD 8.21B.

What is Qiagen NV's P/E ratio?

Qiagen NV's price-to-earnings (P/E) ratio is 20.6.

Does Qiagen NV pay a dividend?

Qiagen NV has a dividend yield of 0.6%.

What does Qiagen NV do?

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene...